Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference | Your money

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare virtual conference. Troy Wilson, Ph.D., JD, President and CEO, is scheduled to participate in a panel titled “Bullseye – Targeted Oncology – In with the New” at 10:20 a.m. ET / 7:20 a.m. PT on Tuesday, August 9, 2022.

A live audio webcast of the panel will be available in the Investors section of Kura’s website at www.kuraoncology.comwith a replay available shortly after the live event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib (KO-539), a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed/refractory AML, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable FTI, has been granted Breakthrough Therapy designation for the treatment of patients with HRAS mutant HNSCC and is currently in registration-directed trial (AIM-HN) in patients with this devastating disease. Additionally, Kura is conducting a Phase 1/2 (KURRENT-HN) trial of tipifarnib in combination with the PI3Kα inhibitor alpelisib to treat larger genetic subsets of HNSCC patients, including those with tumors depend on HRAS and/or PI3Kα pathways. The Company is also preparing to initiate a Phase 1 trial (KURRENT-LUNG) of tipifarnib in combination with osimertinib in treatment-naïve locally advanced/metastatic EGFR mutated NSCLC. Kura intends to perform initial clinical evaluation with tipifarnib while concurrently advancing the company’s next-generation FTI, KO-2806, through IND-enabling studies. For more information, please visit Kura’s website at www.kuraoncology.com.

contacts

Company: Pete De Spain Senior Vice President, Investor Relations and Corporate Communications (858) 500-8803 pete@kuraoncology.com

Investors: Robert H. Uhl Managing Director ICR Westwicke (858) 356-5932 robert.uhl@westwicke.com

Media: Jason Spark General Manager Canale Communications (619) 849-6005 jason@canalecomm.com

Copyright 2022 GlobeNewswire, Inc.